Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2014

Supporting Information

Palladium-Catalyzed Dehydration of Amides to Nitriles

Wandi Zhang,[†] Christopher W. Haskins,[†] Yang Yang, and Mingji Dai^{*} Department of Chemistry and Center for Cancer Research, Purdue University, 560 Oval Drive, West Lafayette, IN 47907, United States

CONTENTS

Part 1. Experimental Procedure and Analytical Data	S3
Part 2. X-Ray Structure of 3a	S11
Part 3. NMR Spectra of New Compounds	.S12

Part 1. Experimental Procedure and Analytical Data

General Methods: NMR spectra were recorded on (¹H at 400 MHz, 500 MHz and ¹³C at 100 MHz, 125 MHz) spectrometers. Chemical shifts (δ) were given in ppm with reference to solvent signals [¹H NMR: CHCl₃ (7.26); ¹³C NMR: CDCl₃ (77.2)]. Column chromatography was performed on silica gel. All reactions sensitive to air or moisture were carried out under argon or nitrogen atmosphere in dry and freshly distilled solvents under anhydrous conditions, unless otherwise noted. Anhydrous MeCN was distilled over calcium hydride under N₂. All other solvents and reagents were used as obtained from commercial sources without further purification.

General Procedure for the Synthesis of Amides

I. General Procedure for the Synthesis of Amides 1a, 1c-e.



To a stirred solution of diisopropyl amine (1.1 equiv) in THF cooled to 0 °C was added *n*butyllithium (1.1 equiv). The mixture was stirred at -78 °C for 30 min before ketone **S1** (1.0 equiv) was added dropwise as a solution of THF to the LDA solution. The mixture was stirred at -78 °C for 1 hour. *N*-Phenyl-bis(trifluoromethanesulfonimide) (1.05 equiv) was added at -78 °C. The mixture was warmed to 0 °C and stirred for 2 h. The reaction was quenched with H₂O and extracted with Et₂O. The organic layers were washed with 1M aqueous NaOH, dried over MgSO₄, filtered and concentrated. The crude product was concentrated and purified by flash chromatography to yield the corresponding triflate **S2**. To a stirring solution of Pd(PPh₃)₂Cl₂ (0.1 equiv) in DMF, a solution of vinyl triflate **S2** (1.0 equiv), triethylamine (3.4 equiv), and acrylamide (1.8 equiv) in DMF was added dropwise. The mixture was heated to 75 °C for 5 h. The mixture was diluted with H₂O and extracted using Et₂O and CH₂Cl₂. The organic layers were washed with brine and dried over Na₂SO₄. The crude product was concentrated and recrystallized using Hex:EtOAc (4:1) to yield amide **1a, 1c-e**.

II. General Procedure for the Synthesis of Amides 1f and 1m.



To a stirring solution of $Pd(PPh_3)_2Cl_2$ (0.1 equiv) in DMF, a solution of the corresponding iodide **S3** (1.0 equiv), triethylamine (3.4 equiv), and acrylamide (1.8 equiv) in DMF was added dropwise.

The mixture was heated to 75 °C for 5 h. The mixture was diluted with H_2O and extracted with Et_2O and CH_2Cl_2 . The organic layers were washed with brine and dried over Na_2SO_4 . The crude product was concentrated and recrystallized using Hex:EtOAc (4:1) to yield amides **1f** and **1m**.

VI. General Procedure for the Synthesis of Other Amides

To corresponding carboxylic acid S4 (3.0 mmol), an excess of $SOCl_2$ (5 mL) was added to the reaction flask. The solution was then refluxed for several hours (1-5 h) or until solution was no longer fuming. The excess $SOCl_2$ was removed under vacuum. The crude product was dissolved in 5 mL of THF and cooled to 0 °C. An excess amount of NH₄OH (28-30% NH₃, 15 mL) was added to the solution slowly. The solution was allowed to stir for 0.5 h after addition at 0 °C. The solution was extracted using (1x10 mL) THF and (3x10 mL) EtOAc. The product was dried over anhydrous Na₂SO₄ or MgSO₄, filtered and concentrated to give the desired amides 1g-i, and 4a-j.

Compounds $1b^1$, $1j^2$, $1k^2$, and $1i^2$ were synthesized according to the literature route.

General Procedure for the Dehydration of Amides and Analytical Data

General Procedure A for the Dehydration of Amides

A mixture of amide (50 mg), $PdCl_2$ (0.1 equiv), AgOAc (3.0 equiv), and LiCl (2.0 equiv) in MeCN (2.5 mL) in a 2 dram vial were heated at 80 °C for 24 h or until the starting material was consumed. The palladium catalyst was filtered off through a plug of celite and washed with EtOAc. The crude solution was concentrated and purfied via column chromatography (Hex/EtOAc = 10/1).

General Procedure **B** for Dehydration of Amides

A mixture of amide (50 mg), $Pd(PPh_3)_2Cl_2$ (0.1 equiv), $Cu(OAc)_2$ (3.0 equiv) in MeCN (2.5 mL) in a 2 dram vial were heated at 80 °C for 24 hours or until the starting material was consumed. The palladium catalyst was filtered off through a plug of celite and washed with EtOAc. The crude solution was concentrated and purified via column chromatography (Hex/EtOAc = 10/1).

3a was prepared using general procedure **A**; 96% yield. ¹H NMR (400 MHz, CDCl₃): δ = 7.33 (t, J = 7.2 Hz, 2H), 7.26-7.22 (m, 3H), 7.06 (d, J = 16.4 Hz, 1H), 6.25 (s, 1H), 5.23 (d, J = 16.4 Hz,

1H), 2.87-2.80 (m, 1H), 2.56 (d, J = 19.6 Hz, 1H), 2.37 (dd, J = 19.6, 10.4 Hz, 1H), 2.26 (d, J = 3.2 Hz, 1H), 2.08 (dd, J = 12.6, 3.2 Hz, 1H), 1.87-1.77 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 153.1$, 145.7 139.2, 134.5, 128.7, 126.9, 126.6, 118.9, 93.2, 39.6, 34.4, 29.1; IR (film): 2921, 2209, 1626, 1597, 1452, 1181 cm⁻¹; MS (ESI): m/z 232.0 [M+Na]⁺.



3b was prepared using general procedure **A**; 69% yield. ¹H NMR (400 MHz, CDCl₃): δ = 7.46 (dd, J = 6.4, 2.0 Hz, 2H), 7.40-7.34 (m, 3H), 7.15 (dd, J = 15.6, 12.0 Hz, 1H), 6.91-6.78 (m, 2H), 5.44 (d, J = 16.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 150.4, 141.5, 135.4, 129.8, 129.0, 127.5, 125.5, 118.4, 98.4. Our spectra are consistent with literature report.³

3c was prepared using general procedure **A**; 82%. ¹H NMR (400 MHz, CDCl₃): δ = 7.34-7.30 (m, 2H), 7.26-7.24 (m, 1H), 7.18-7.16 (m, 1H), 6.96 (d, *J* = 16.8 Hz, 1H), 6.17 (t, *J* = 4.0 Hz, 1H), 5.34 (d, *J* = 16.4 Hz, 1H), 2.87 (dd, *J* = 13.2, 2.8 Hz, 1H), 2.57-2.48 (m, 2H), 2.37-2.17 (m, 2H), 1.78-1.60 (m, 3H), 1.43 (tt, *J* = 13.6, 4.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ = 153.1, 140.5, 140.4, 138.4, 129.0, 128.6, 126.4, 119.0, 92.7, 38.6, 34.3, 26.6, 24.3, 16.6; IR (film): 2936, 2215, 1622, 1599, 1266, 968 cm⁻¹; MS (ESI): *m/z* 246.0 [M+Na]⁺.



3d was prepared using general procedure **A**; 49%. ¹H NMR(400 MHz, CDCl₃): δ = 7.00 (d, *J* = 16.0 Hz, 1H), 5.99 (t, *J* = 4.4 Hz, 1H), 5.20 (d, *J* = 16.4 Hz, 1H), 3.57 (d, *J* = 11.2 Hz, 2H), 3.47 (d, *J* = 11.6 Hz, 2H), 2.56 (s, 2H), 2.22-2.20 (m, 2H), 2.03 (t, *J* = 6.4 Hz, 2H), 1.03 (s, 3H), 0.93 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 152.4, 135.6, 134.1, 118.1, 96.6, 93.8, 70.5, 35.9, 30.3, 26.9. 22.8, 22.6, 21.9; IR (film): 2959, 2217, 1633, 1266, 1039, 968 cm⁻¹; MS (ESI): *m/z* 256.1 [M+Na]⁺.



3e was prepared using general procedure **A**; 51%. ¹H NMR (400 MHz, CDCl₃): δ = 6.93 (dd, J = 16.8, 1.2 Hz, 1H), 6.42 (d, J = 3.2 Hz, 1H), 5.46 (dd, J = 16.4, 1.2 Hz, 1H), 2.41 (t, J = 3.6 Hz, 1H), 1.96-1.90 (m, 1H), 1.64-1.59 (m, 1H), 1.14 (s, 3H), 1.09-0.95 (m, 2H), 0.08 (s, 3H), 0.76 (s

3H); ¹³C NMR (100 MHz, CDCl₃): δ = 146.2, 145.5, 142.8, 119.2, 94.0, 57.6, 54.2, 52.3, 31.4, 25.0, 19.5, 19.3, 12.6; IR (film): 2959, 2214, 1606, 1265, 966, 910 cm⁻¹; MS (ESI): *m/z* 210.1 [M+Na]⁺.

3f was prepared using general procedure **A**; 59%. ¹H NMR (500 MHz, CDCl₃): δ = 7.28 (d, *J* = 16.5 Hz, 1H), 6.93-6.92 (m, 2H), 6.82 (dd, *J* = 7.0, 1.0 Hz, 1H), 6.02 (s, 2H), 5.67 (d, *J* = 16.5 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 150.5, 150.1, 148.7, 128.1, 124.2, 118.6, 108.8, 105.7, 101.9, 94.0. Our spectra are consistent with literature report.⁴



3g was prepared using general procedure **A**; 80%. ¹H NMR (400 MHz, CDCl₃): δ = 8.28 (d, *J* = 8.8 Hz, 2H), 7.63 (dd, *J* = 6.8, 2.0 Hz, 2H), 7.47 (d, *J* = 16.8 Hz, 1H) 6.05 (d, *J* = 16.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 149.2, 147.9, 139.3, 128.3, 124.5, 117.1, 101.2. Our spectra are consistent with literature report.⁵

3h was prepared using general procedure A; 87%. ¹H NMR (500 MHz, CDCl₃): δ = 7.29 (d, J = 16.5 Hz, 1H), 6.64 (s, 2H), 5.78 (d, J = 16.5 Hz, 1H), 3.86 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ = 153.7, 150.5, 141.0, 129.1, 118.3, 104.8, 95.5, 61.1, 56.3. Our spectra are consistent with literature report.⁶

3i was prepared using general procedure **A**; 78%. ¹H NMR (400 MHz, CDCl₃): δ = 7.45-7.37(m, 3H), 7.34 (d, *J* = 1.7 Hz, 1H), 7.32 (s, 1H), 7.22 (s, 1H), 2.15 (d, *J* = 1.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 144.3, 134.0, 129.2, 129.2, 128.6, 121.2, 109.6, 16.7. Our spectra are consistent with literature report.⁷



3j was prepared using general procedure **A**; 59%. ¹H NMR (400 MHz, CDCl₃): δ = 7.74 (s, 1H), 7.70 (d, *J* = 7.89 Hz, 1H), 7.35 (d, *J* = 7.80 Hz, 1H), 7.21 (d, *J* = 6.10, 1H), 7.1 (t, *J* = 7.83, 1H), 5.8 (d, *J* = 16.6, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 148.7, 139.8, 135.9, 135.4, 130.6, 126.4, 117.5, 97.79, 94.71; IR(film): 2957, 2931, 2220, 1620, 1560, 1409 cm⁻¹; MS (ESI): *m/z* 277.9 [M+Na]⁺.



3k was prepared using general procedure **A**; 60%. ¹H NMR (400 MHz, CDCl₃): δ = 7.60 (t, *J* = 1.8 Hz, 1H), 7.57 (d, *J* = 7.93 Hz, 1H), 7.38-7.27 (m, 3H), 5.89 (d, *J* = 16.7, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 149.0, 135.6, 134.1, 130.7, 130.2, 126.1, 123.4, 117.7, 98.2. Our spectra are consistent with literature report.⁸



3I (56%)

31 was prepared using general procedure **A**; 56%. ¹H NMR (400 MHz, CDCl₃): δ = 7.55 (d, *J* = 17.0, 1H), 7.38 (d, *J* = 8.1 Hz, 2H), 7.24 (t, *J* = 8.4 Hz, 1H), 6.19 (d, *J* = 17.0, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 144.3, 134.9, 130.9, 130.6, 129.2, 117.3, 105.9. Our spectra are consistent with literature report.⁹



3m was prepared using general procedure **A**; 91%. ¹H NMR (500 MHz, CDCl₃): δ = 7.46-7.38 (m, 6H), 5.88 (d, *J* = 17.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 150.7, 133.6, 131.3, 129.2, 127.4, 118.3, 96.4. Our spectra are consistent with literature report.¹⁰

MeO → = = N 5a (87%)

5a was prepared using general procedure **B**; 87%. ¹H NMR (400 MHz, CDCl₃): δ = 7.36 (t, *J* = 8.48 Hz, 1H), 7.23(t, *J* = 10.57 Hz, 1H), 7.12 (br s, 2H), 3.82 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 159.5, 130.2,124.4, 119.2, 118.6, 116.7, 113.1, 55.4. Our spectra are consistent with

literature report.¹¹

5b was prepared using general procedure **B**; 83%. ¹H NMR (400 MHz, CDCl₃): δ = 7.14-7.04 (m, 3H), 4.00 (s, 3H), 3.88 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 152.6, 151.6, 124.3, 116.9, 116.2, 106.9, 61.6, 56.0. Our spectra are consistent with literature report.¹²



5c was prepared using general procedure **B**; 53%. ¹H NMR (500 MHz, CDCl₃): δ = 7.87 (d, *J* = 7.5 Hz, 2H), 7.80-7.78 (m, 4H), 7.64 (t, *J* = 7.5 Hz, 1H), 7.51 (t, *J* = 7.5 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃): δ = 195.2, 141.3, 136.4, 133.5, 132.3, 130.4, 130.2, 128.8, 118.1, 115.8. Our spectra are consistent with literature report.¹³



5d was prepared using general procedure **B**; 77%. ¹H NMR (500 MHz, CDCl₃): δ = 8.26 (d, *J* = 2.0 Hz, 1H), 7.78 (dd, *J* = 3.0, 2.0 Hz, 1H), 7.51 (d, *J* = 8.0 Hz, 1H), 2.68 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 149.4, 139.1, 135.8, 134.1, 128.5, 116.7, 111.5. Our spectra are consistent with literature report.¹⁴



5e was prepared using general procedure **B**; 77%. ¹H NMR (500 MHz, CDCl₃): $\delta = 8.02$ (d, J = 8.5 Hz, 1H), 7.68-7.65 (m, 2H), 2.62 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 151.6$, 136.6, 134.7, 130.8, 125.3, 117.0, 116.7, 20.0. Our spectra are consistent with literature report.¹⁴



5f was prepared using general procedure **B**; 88%. ¹H NMR (CDCl₃, 400 MHz) δ = 7.36 (t, *J* = 6.85 Hz, 2H), 7.29 (m, 1H), 7.26 (d, *J* = 6.91 Hz, 2H), 2.97 (t, *J* = 7.09 Hz, 2H), 2.62 (t, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ = 138.0, 128.8, 128.2, 127.1, 119.1, 31.5, 19.2. Our spectra are

consistent with literature report.¹⁵



5g was prepared using general procedure **B**; 95%. ¹H NMR (CDCl₃, 400 MHz) δ = 7.30 (t, *J* = 7.17 Hz, 2H), 7.19 (m, 3H), 2.67 (t, *J* = 7.23 Hz, 2H), 2.35 (t, *J* = 7.09 Hz, 2H), 2.27 (s, 3H), 1.80 (m, 2H), 1.71 (m, 2H); ¹³C NMR (CDCl₃, 100 MHz) δ = 141.1, 128.4, 128.3, 126.0, 119.5, 34.9, 30.2, 24.7, 17.0. Our spectra are consistent with literature report.¹⁵



5h (93%)

5h was prepared using general procedure **B**; 93%. ¹H NMR (400 MHz, CDCl₃): δ = 7.38-7.34 (m, 4H), 7.31-7.25 (m, 6H), 4.40 (t, *J* = 9.5 Hz, 1H), 3.04 (d, *J* = 9.5 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 141.3, 129.0, 127.6, 127.5, 47.2, 24.3. Our spectra are consistent with literature report.¹⁶

5i was prepared using general procedure **B**; 93%. ¹H NMR (400 MHz, CDCl₃): $\delta = 3.09$ (t, J = 7.28 Hz, 2H), 2.68 (t, J = 7.32 2H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 146.7$, 144.2, 142.3, 139.8,139.2, 136.7, 117.9, 111.2, 109.0, 19.1, 17.4; ¹⁹F NMR (376 MHz, CDCl₃): -144.68, -155.95, -162.75; IR (film): 2252, 1522, 1502, 1040, 941, 876 cm⁻¹; MS (ESI): m/z 244.0 [M+Na]⁺.

5j was prepared using general procedure **B**; 78%. ¹H NMR (500 MHz, CDCl₃): δ = 2.33 (t, *J* = 7.0 Hz, 2H), 1.68-1.62 (m, 2H), 1.47-1.41 (m, 2H), 1.31-1.25 (m, 22H), 0.88 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 120.0, 32.0, 29.8, 29.8, 29.7, 29.6, 29.5, 29.4, 28.9, 28.8, 25.5, 22.8, 17.2, 14.2. Our spectra are consistent with literature report.¹⁷

References

- [1] C. Johnson and B. Zhang, Tetrahedron Lett., 1995, 51, 9253.
- [2] J. Petrova, S. Momchilova and N. G. Vassiley, *Phosphorus, Sulfur, and Silicon and the Related Elements*, 2000, **164**, 87.
- [3] H. Andersson, X. Wang, M. Björklund, R. Olsson and F. Almqvist, *Tetrahedron Lett.*, 2007, 48, 6941.
- [4] C. J. Morton, R. Gilmour, D. M. Smith, P. Lightfoot, A. M. Z. Slawin and E. J. MacLean, *Tetrahedron*, 2002, 58, 5547.
- [5] B. V. Rokade and K. R. Prabhu, J. Org. Chem., 2012, 77, 5364.
- [6] M. D'Auria and R. Racioppi, *Tetrahedron*, 1997, 53, 17307.
- [7] T. Tomioka, R. Sankranti, T. G. Vaughan, T. Maejima and T. Yanase, J. Org. Chem., 2011, 76, 8053.
- [8] D. A. R. Happer and B. E. Steenson, J. Chem. Soc., Perkin Trans. 2, 1988, 19.
- [9] H. Dong, M. Shen, J. E. Redford, B. J. Stokes, A. L. Pumphrey and T. G. Driver, Org. Lett., 2007, 9, 5191.
- [10] G. Ishii, R. Harigae, K. Moriyama and H. Togo, Tetrahedron, 2013, 69, 1462.
- [11] W. Zhou, J. Xu, L. Zhange and N. Jiao, Org. Lett., 2010, 12, 2888.
- [12] S. Ushijima, K. Moriyama and H. Togo, Tetrahedron, 2011, 67, 958.
- [13] X. Peng, N. Fukui, M. Mizuta and H. Suzuki, Org. Biomol. Chem., 2003, 1, 2326.
- [14] T. Mino, T. Koizumi, M. Shibuya, K. Hirai, M. Sakamoto and T. Fujita, *Heterocycles*, 2011, 83, 163.
- [15] T. Kuwahara, T. Fukuyama and I. Ryu, Chem. Lett., 2013, 42, 1163.
- [16] Y. Nakao, J. Chen, H. Imanaka, T. Hiyama, Y. Ichikawa, W.-L. Duan, R. Shintani and T. Hayashi, J. Am. Chem. Soc., 2007, 129, 9137.
- [17] Y. Suzuki, K. Moriyama and H. Togo, Tetrahedron, 2011, 67, 7956.



Figure S1. X–Ray Structure of 3a



Part 3. NMR Spectra of New Compounds



Figure S4. ¹H NMR of 3c (400 MHz, CDCl₃)







Figure S9. ¹³C NMR of 3e (100 MHz, CDCl₃)



Figure S10. ¹H NMR of 3j (400 MHz, CDCl₃)



Figure S11. ¹³C NMR of 3j (125 MHz, CDCl₃)



